Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANASDAQ:CRONTSE:TEVNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$31.32$24.33M0.4123,988 shs237,144 shsCRONCronos Group$2.08+1.0%$1.82$1.60▼$3.14$801.65M1.061.33 million shs2.97 million shsTEVTervitaC$0.00C$1.69▼C$6.46C$672.00MN/A79,738 shs15,893 shsTLRYTilray$0.44-0.3%$0.54$0.41▼$2.23$442.86M1.9528.40 million shs22.70 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%-4.14%-5.00%-38.73%CRONCronos Group+0.98%+11.35%+19.77%+3.00%-29.69%TEVTervita0.00%0.00%0.00%0.00%0.00%TLRYTilray-2.00%+2.11%-9.33%-53.21%-78.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics2.5968 of 5 stars3.05.00.04.20.00.80.0CRONCronos Group0.7682 of 5 stars0.03.00.00.02.60.01.3TEVTervitaN/AN/AN/AN/AN/AN/AN/AN/ATLRYTilray1.6632 of 5 stars3.12.00.00.01.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 2.00Hold$72.00∞ UpsideCRONCronos Group 0.00N/AN/AN/ATEVTervita 0.00N/AN/AN/ATLRYTilray 2.25Hold$1.92335.61% UpsideCurrent Analyst Ratings BreakdownLatest TLRY, CARA, CRON, and TEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TLRYTilrayRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilrayPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00CRONCronos Group$124.59M6.43N/AN/A$2.87 per share0.72TEVTervitaC$1.36B0.00N/A29.62C$1.58 per share0.00TLRYTilray$210.48M2.10N/AN/A$4.14 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ACRONCronos Group-$73.96M$0.13N/A69.331.74-42.65%-2.56%-2.47%N/ATEVTervitaN/A-C$0.01N/AN/AN/AN/AN/AN/AN/ATLRYTilray-$244.98M-$1.05N/AN/AN/A-30.95%-4.40%-3.57%N/ALatest TLRY, CARA, CRON, and TEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million4/8/2025Q3 2025TLRYTilray-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ATEVTervitaN/AN/AN/AN/AN/ATLRYTilrayN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71CRONCronos GroupN/A24.2423.05TEVTervita440.441.000.86TLRYTilray0.102.541.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%CRONCronos Group8.71%TEVTervitaN/ATLRYTilray9.35%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%CRONCronos Group6.90%TEVTervitaN/ATLRYTilray0.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableCRONCronos Group450385.41 million356.14 millionOptionableTEVTervita36,800115.66 millionN/ANot OptionableTLRYTilray2,6501.01 billion929.50 millionOptionableTLRY, CARA, CRON, and TEV HeadlinesRecent News About These CompaniesTilray (NASDAQ:TLRY) Stock Price Down 1.4% - Here's What HappenedMay 15 at 2:45 PM | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Down 2.1% - Should You Sell?May 14 at 3:40 PM | marketbeat.comTilray Brands Announces the Launch of XMG Atomic Sours: New THC Beverages and EdiblesMay 14 at 7:00 AM | globenewswire.comTilray Inc (NASDAQ:TLRY) Shares Purchased by Dimensional Fund Advisors LPMay 14 at 3:19 AM | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Up 1.2% - Here's WhyMay 13 at 4:54 PM | marketbeat.comBest Canadian Marijuana Stocks for U.S. Market ExposureMay 13 at 10:00 AM | marijuanastocks.com2 Stocks Near Their 52-Week Lows That Still Aren't Worth BuyingMay 13 at 4:14 AM | fool.comTilray (NASDAQ:TLRY) Shares Down 2.1% - Here's WhyMay 10, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Trading Up 1.5% - Time to Buy?May 9, 2025 | marketbeat.comTop 3 Marijuana Stocks For Better Investing 2025May 9, 2025 | marijuanastocks.com1 Beaten-Down Stock-Split Company to Avoid in 2025 and BeyondMay 9, 2025 | fool.comTilray (NASDAQ:TLRY) Trading 2.6% Higher - Should You Buy?May 8, 2025 | marketbeat.comCannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?May 8, 2025 | zacks.comShock Top: A Bold Rebrand for a Craft Beer IconMay 8, 2025 | globenewswire.comTilray (NASDAQ:TLRY) Trading Down 1% - What's Next?May 7, 2025 | marketbeat.comWhat's Going On With Tilray Brands Stock On Tuesday?May 6, 2025 | benzinga.comTilray (NASDAQ:TLRY) Stock Price Down 3.3% - Here's WhyMay 6, 2025 | marketbeat.comBest Cannabis Stocks To Follow Today - May 5thMay 6, 2025 | marketbeat.comBlue Point Brewing Co. Announces the Return of Delayed PilsnerMay 6, 2025 | globenewswire.comHigh Potential: Canadian Cannabis Stocks Making Waves in May 2025May 4, 2025 | marijuanastocks.comTilray (NASDAQ:TLRY) Trading 3.1% Higher - Here's What HappenedMay 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitU.S. Regulators Target CrowdStrike: Is It a Signal or Noise? By Chris Markoch | May 14, 2025View U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? TLRY, CARA, CRON, and TEV Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Cronos Group NASDAQ:CRON$2.08 +0.02 (+0.97%) As of 04:00 PM EasternCronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Tervita TSE:TEVTervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada.Tilray NASDAQ:TLRY$0.44 0.00 (-0.32%) As of 04:00 PM EasternTilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
